GRACELL BIOTECHNOLOGIES INC's ticker is GRCL and the CUSIP is 38406L103. A total of 34 filers reported holding GRACELL BIOTECHNOLOGIES INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,452 | -50.0% | 6,754 | -33.8% | 0.00% | – |
| Q2 2023 | $38,896 | +362.2% | 10,209 | +125.7% | 0.00% | – |
| Q1 2023 | $8,415 | +0.8% | 4,524 | +24.6% | 0.00% | – |
| Q4 2022 | $8,349 | -44.3% | 3,630 | -21.6% | 0.00% | – |
| Q3 2022 | $15,000 | -46.4% | 4,630 | -9.9% | 0.00% | – |
| Q2 2022 | $28,000 | +27.3% | 5,140 | -46.1% | 0.00% | – |
| Q1 2022 | $22,000 | -38.9% | 9,540 | +61.4% | 0.00% | – |
| Q4 2021 | $36,000 | -80.7% | 5,910 | -56.1% | 0.00% | – |
| Q3 2021 | $187,000 | – | 13,464 | +134540.0% | 0.00% | – |
| Q2 2021 | $0 | -100.0% | 10 | -99.9% | 0.00% | – |
| Q1 2021 | $119,000 | – | 7,712 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 3,445,973 | $8,029,000 | 0.68% |
| Paradigm Biocapital Advisors LP | 783,445 | $1,825,000 | 0.48% |
| Orbimed Advisors | 7,884,870 | $18,372,000 | 0.30% |
| Vivo Capital, LLC | 961,359 | $2,240,000 | 0.15% |
| EcoR1 Capital, LLC | 1,559,710 | $3,634,000 | 0.11% |
| Temasek Holdings (Private) Ltd | 9,901,940 | $23,071,520 | 0.10% |
| Capital International, Inc./CA/ | 2,335,476 | $5,442,000 | 0.06% |
| Virtus ETF Advisers LLC | 24,728 | $58,000 | 0.03% |
| Capital International Sarl | 228,149 | $532,000 | 0.03% |
| FEDERATED HERMES, INC. | 1,298,578 | $3,026,000 | 0.01% |